Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience

Brentuximab vedotin (BV), an anti-CD30-specific antibody-drug conjugate (ADC), is one of the most promising new agents employed in the treatment of peripheral T-cell lymphomas (PTCLs), in particular, systemic anaplastic large cell lymphomas (sALCL).1,2 The drug has proved to be safe and effective both as a single agent in relapsed/refractory disease and in combination with standard chemotherapy in the first-line setting.3-7
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research